Bevacizumab in Ovarian Cancer Extends Overall SurvivalBevacizumab in Ovarian Cancer Extends Overall Survival

Adding the antiangionic agent to combination chemotherapy shows a clinically meaningful improvement in overall survival compared with standard chemotherapy alone. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

In this study, a green approach by utilizing Acacia nilotica leaves (ANL) extract to produce silver nanoparticles (AgNPs) has been made. The biosynthesized AgNPs displayed surface plasmon resonance (SPR) centered at 430 nm. Fourier transform infrared spectroscopy (FTIR) and energy-dispersive spectra (EDS) results showed the contribution of phyto-constituents of ANL in the reduction, capping and stabilizing matrix for AgNPs. The AgNPs were characterized by X-ray diffraction (XRD), and high resolution transmission electron microscopy (HR-TEM) revealed the synthesized ANL-AgNPs were crystalline and spherical forms having ab...
Source: Journal of the Taiwan Institute of Chemical Engineers - Category: Chemistry Source Type: research
CONCLUSIONS:: This report describes an extremely rare case of a tracheal IMT, underlying the key role of radiotherapy as adjuvant treatment able to definitively cure IMT, limiting systemic chemotherapy-related toxicity. PMID: 30900517 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Authors: Del-Pozo-Lérida S, Salvador C, Martínez-Soler F, Tortosa A, Perucho M, Giménez-Bonafé P Abstract Survival rates in oncological patients have been steadily increasing in recent years due to the greater effectiveness of novel oncological treatments, such as radio‑ and chemotherapy. However, these treatments impair the reproductive ability of patients, and may cause premature ovarian failure in females and azoospermia in males. Fertility preservation in both female and male oncological patients is nowadays possible and should be integrated as part of the oncological healthcare. T...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
ConclusionBowel perforation in the elderly, presenting with cachexia and treatment-induced pancytopenia for advanced ovarian cancer, is often a harbinger of early death. Selected patients may benefit from a minimally invasive approach by an experienced gynecologic oncologist instead of vertical laparotomy, abdominal washout, diversion and the potential sequelae of an open abdomen.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
. Oza High grade serous ovarian cancer (HGSOC) is the most common epithelial ovarian cancer, harbouring more than 20% germline or somatic mutations in the tumour suppressor genes BRCA1 and BRCA2. These genes are involved in both DNA damage repair process via homologous recombination (HR) and transcriptional regulation. BRCA mutation confers distinct characteristics, including an increased response to DNA-damaging agents, such us platinum chemotherapy and poly-ADP ribose polymerase inhibitors (PARPi). However, several mechanisms of resistance to these agents have been described, including increased HR capacity through r...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Authors: Han S, Dwivedi P, Mangrio FA, Dwivedi M, Khatik R, Cohn DE, Si T, Xu RX Abstract The current clinical paradigm for ovarian cancer treatment has a poor prognosis, partially due to the efficacy and toxicity concerns associated with the available chemotherapeutic formulations. To overcome these limitations, we have designed core-shell-structured paclitaxel (PTX) laden solid lipid microparticles (PTX-SLMPs) for intraperitoneal treatment of ovarian cancer. A single-step coaxial electro hydrodynamic atomization (CEHDA) process has been explored to synthesize core-shell structure of PTX-SLMPs with the particle si...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Publication date: Available online 20 March 2019Source: European Journal of Surgical OncologyAuthor(s): Matthieu Siebert, Mohammad Alyami, Frederic Mercier, Colin Gallice, Laurent Villeneuve, Nathalie Laplace, Guillaume Passot, Naoual Bakrin, Olivier Glehen, Vahan KepenekianAbstractIntroductionPressurized intraperitoneal aerosol chemotherapy (PIPAC) is a promising technic for unresectable peritoneal metastasis (PM). Targeted therapies such as bevacizumab have demonstrated their efficacy in advanced colorectal and ovarian cancer. We aimed to evaluate the feasibility and safety of this bidimensional therapeutic association.M...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Authors: Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE, Choi EK Abstract OBJECTIVE: Somatic TP53 mutation (TP53mut) is a characteristic finding in high-grade serous ovarian cancer (HGSOC). The aim of this study was to assess the clinical efficacy and utility of TP53mut circulating tumor DNA (ctDNA) monitoring as a biomarker for managing HGSOC. METHODS: TP53muts were evaluated in patients who received primary treatment for suspected ovarian cancer at Asan Medical Center. In patients diagnosed with HGSOC and with TP53mut, ctDNA, cancer antigen 125 (CA 125), and computed tomography were followed up according to the treat...
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
AbstractAs a drug class, inhibitors of poly-(ADP-ribose) polymerase (PARP) have had their greatest impact on the treatment of women with epithelial ovarian cancers (EOC), in particular, those with the most common histological subtype, high-grade serous cancer, as it has high rates of homologous recombination (HR) deficiency. PARP inhibition exploits this cancer vulnerability by further disrupting DNA repair, thus leading to genomic catastrophe. Early clinical data demonstrated the effectiveness of PARP inhibition in women with recurrent EOC harbouringBRCA1/2 mutations and those with platinum-sensitive recurrences. Three PA...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
(MedPage Today) -- Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Source: MedPage Today OB/GYN - Category: OBGYN Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Hematology | Ovarian Cancer | Ovaries